Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -22.00p -1.78% 1,216.00p 1,216.00p 1,217.00p 1,236.00p 1,214.00p 1,236.00p 1,002,145.00 13:30:46
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,781.0 860.0 71.3 17.2 10,892.21

Smith & Nephew Share Discussion Threads

Showing 751 to 775 of 775 messages
Chat Pages: 31  30  29  28  27  26  25  24  23  22  21  20  Older
DateSubjectAuthorDiscuss
10/3/2017
09:49
Now Akzo Nobel falls under the global consolidation hammer. Only a matter of time before SN is bought
mamcw
21/2/2017
15:42
Unilever situation underlines attractiveness of UK-based companies whose earnings are global to US predators.
mamcw
09/2/2017
18:58
Nice come back today. Forming a long lower wick to daily candle.
corlis
09/2/2017
17:51
sharp dip at the open but regained nearly all losses to close at 1198. it appears that someone is very keen to accumulate loose stock.
accipitridae
09/2/2017
09:37
dont forget results reflect a period when the CEO took time out for illness and also lost his CFO. SN generates loads of cash and margins are going up now.
accipitridae
09/2/2017
08:38
And down we go on a pretty lacklustre set of results.Doesn't look like we're going to see a marked acceleration in growth in 2017 given a forecast of revenue growth of around 2% and margins,whilst improving,being subject to various "headwinds"."Stryke(r) while the iron's hot" as they say and if they are to rebid,now is a opportune time when the dollar is strong and S&N have undertaken a lot of remedial action.For now,bid expectations will restrict the downside.Along with Astra Zeneca,S&N remains a slow burning fuse that has still to convince the market of its ability to resume a much improved and sustainable growth pattern.I can't help thinking though that global demographics dictates that this company must be very attractive to predators.So,I remain a strong holder.Either they get their act together or get taken over.
steeplejack
08/2/2017
22:07
ok i buy any dips
accipitridae
08/2/2017
10:56
Accipitidae sorry i meant for a LONG
corlis
08/2/2017
08:52
exactly 1200 - what does this mean
accipitridae
06/2/2017
09:24
Chart wise this at 1,200 is starting to show some promise.
corlis
01/2/2017
12:32
This looks like a fairly straightforward f/x play - with so much of S&N's sales worldwide, yet a stock market valuation that in US Dollar terms has fallen sharply, it becomes very affordable to a US based purchaser.
mamcw
26/1/2017
18:21
dont recall ever seeing a company before that is 10% below its all time highs but is actually a dog. it is a dog because it has under-performed its closest peer by 50% and look at it in dollar terms, it is 30% down over 2.5 years.
accipitridae
26/1/2017
15:48
what is the management doing about it?
accipitridae
26/1/2017
15:47
underperformed its key competitor by nearly 50%. that makes this stock a dog and therefore a good reason it should be sold.
accipitridae
26/1/2017
11:43
now J&J is tied up with Actelion could Stryker finally move on S&N ? Stryker could take advantage of the current price disparity in charts above to get S&N at bargain price. J&J Seals $30 Billion Actelion Deal in Push for Rare Disease https://www.bloomberg.com/news/articles/2017-01-26/j-jto-buy-actelion-for-30-billion-spin-off-research-operations
accipitridae
25/1/2017
17:08
but i cannot work out why. any explanations welcomed!
accipitridae
25/1/2017
17:06
nearly 50% under-performance by S&N since the beginning of last year
accipitridae
17/1/2017
08:48
ADRs surged overnight, worth about £12.64
accipitridae
22/12/2016
09:56
looks like J&J might get Actelion after all. perhaps that will enable stryker to finally make a move here? stryker has outperformed S&N by nearly 50% YTD so it could make use of its more expensive equity.
accipitridae
16/12/2016
15:16
could J&J turn in this direction if Actelion goes to Sanofi?
accipitridae
26/11/2016
09:06
Get hip to Smith & Nephew's investment appeal, Goldman advises Share 10:36 25 Nov 2016 The hip and joint replacement specialist trades at a discount to sector peer Stryker Goldman Sachs has lowered its earnings estimates for Smith & Nephew PLC (LON:SN. but still rates the medical technology company’s shares a ‘buy’. The estimate changes follow the third quarter trading update earlier this morning and recent exchange rate movements, and see this year’s earnings per share (EPS) forecast decline 3%, while EPS estimates for the next three years have been shaved by 8%, reflecting weaker growth patterns in the third quarter. “While organic revenue growth this year has fallen short of our expectations (we now expect Smith & Nephew to deliver 1.9% organic revenue growth in 2016, down from the 5% that we had forecast at the beginning of 2016, with the slowdown driven largely by China and the Middle East), we continue to believe that SN.L will accelerate organic revenue growth into the 4%-5% range in 2017 and beyond, given its geographic and product mix (>50% of revenues is in higher-growth markets) and a number of upcoming product launches (Renasys Touch and Connect, Navio in total knee, revision hip, and WereWolf),” the heavyweight US investment bank said. The next catalyst for the share price is likely to be the appointment of a chief financial officer, expected before the end of the year. Goldman’s lowered its price target to 1,310p from 1,370p, on the assumption that Smith & Nephew will trade around 18 times projected EPS for 2018; it currently trades at 15.4 times 2018 EPS, whereas sector peer Stryker Corporation (NYSE:SYK) trades on an earnings multiple of 17.4, despite a comparable growth outlook. Goldman deems the disparity as unwarranted, and in fact suggests S&N should trade at a premium to Stryker, thanks to the possibility of being taken out by a competitor.
accipitridae
23/11/2016
11:51
could be massive bargin sub £11. underperformed Stryker 45% YTD. is this crazy?
accipitridae
22/11/2016
13:21
Google Finance has price/sales at 2.61 vs 4.20 for Stryker and 4.46 for J&J. Are these numbers correct?
accipitridae
22/11/2016
13:09
Smith & Nephew: UBS reiterates neutral with a 1160p target
philanderer
22/11/2016
11:37
Downside must be limited. Time to buy.
its the oxman
Chat Pages: 31  30  29  28  27  26  25  24  23  22  21  20  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170330 12:46:14